KR101820761B1 - Composition for improving sleep disturbance and sleep inducing - Google Patents
Composition for improving sleep disturbance and sleep inducing Download PDFInfo
- Publication number
- KR101820761B1 KR101820761B1 KR1020160053430A KR20160053430A KR101820761B1 KR 101820761 B1 KR101820761 B1 KR 101820761B1 KR 1020160053430 A KR1020160053430 A KR 1020160053430A KR 20160053430 A KR20160053430 A KR 20160053430A KR 101820761 B1 KR101820761 B1 KR 101820761B1
- Authority
- KR
- South Korea
- Prior art keywords
- sleep
- extract
- composition
- dried
- casein
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000007958 sleep Effects 0.000 title claims description 36
- 208000019116 sleep disease Diseases 0.000 title claims description 23
- 230000001939 inductive effect Effects 0.000 title claims description 20
- 208000022925 sleep disturbance Diseases 0.000 title claims description 10
- 239000000284 extract Substances 0.000 claims abstract description 47
- 239000005018 casein Substances 0.000 claims abstract description 35
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000021240 caseins Nutrition 0.000 claims abstract description 35
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 34
- 235000003228 Lactuca sativa Nutrition 0.000 claims abstract description 23
- 241000208822 Lactuca Species 0.000 claims abstract description 21
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 17
- 239000001103 potassium chloride Substances 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 230000006872 improvement Effects 0.000 claims description 14
- 208000020685 sleep-wake disease Diseases 0.000 claims description 12
- 244000025254 Cannabis sativa Species 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 241000206609 Porphyra Species 0.000 claims description 4
- 201000002154 Pterygium Diseases 0.000 claims description 3
- 239000000287 crude extract Substances 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 229940049706 benzodiazepine Drugs 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract description 5
- 229960002695 phenobarbital Drugs 0.000 abstract description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract description 4
- 102000011632 Caseins Human genes 0.000 description 34
- 108010076119 Caseins Proteins 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 241000218228 Humulus Species 0.000 description 9
- 206010022437 insomnia Diseases 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 240000008415 Lactuca sativa Species 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 102000027484 GABAA receptors Human genes 0.000 description 3
- 108091008681 GABAA receptors Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 3
- 241000237502 Ostreidae Species 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960003987 melatonin Drugs 0.000 description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 235000020636 oyster Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 244000025221 Humulus lupulus Species 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 244000126014 Valeriana officinalis Species 0.000 description 2
- 235000013832 Valeriana officinalis Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960004381 flumazenil Drugs 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002438 stress hormone Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000016788 valerian Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010000372 Accident at work Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241001249699 Capitata Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001299819 Hordeum vulgare subsp. spontaneum Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 235000010702 Insulata Nutrition 0.000 description 1
- 244000165077 Insulata Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 241001505935 Phalaenopsis Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241001505102 Valeriana fauriei Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- -1 chlorine ions Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
- A23V2250/54246—Casein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 천연물 유래의 구성성분들로 이루어져 페노바비탈류, 벤조다이아제핀류를 포함한 합성의약품이 가지는 부작용을 유발하지 않고, 안전성을 확보할 수 있으며, GABAA-벤조다이아제핀 수용체에 친화력을 가져 수면장애를 개선할 수 있는 수면장애 개선 및 수면유도 조성물에 관한 것으로서, 카제인 또는 카제인 가수분해물 10 내지 90중량부와 염화칼륨 2 내지 10중량부를 포함함을 특징으로 하며, 여기에 쥐오줌풀 추출물, 호프 추출물, 상추 추출물 이들 중 2이상의 혼합물로 이루어지는 군으로부터 선택되는 어느 하나의 추출물을 더 포함할 수 있다.The present invention is based on the finding that the present invention can provide safety without causing side effects of synthetic drugs including phenobarbital, benzodiazepine, and the like, and has an affinity for GABAA-benzodiazepine receptor, Wherein the composition comprises 10 to 90 parts by weight of casein or casein hydrolyzate and 2 to 10 parts by weight of potassium chloride, wherein the composition comprises at least one member selected from the group consisting of a root extract, a hop extract, a lettuce extract And an extract of any one selected from the group consisting of a mixture of two or more thereof.
Description
본 발명은 수면장애 개선 및 수면유도 조성물에 관한 것으로, 보다 상세하게는 천연물 유래의 구성성분들로 이루어져 페노바비탈류, 벤조다이아제핀류를 포함한 합성의약품이 가지는 부작용을 유발하지 않고, 안전성을 확보할 수 있으며, GABAA-벤조다이아제핀 수용체에 친화력을 가져 수면장애를 개선할 수 있는 수면장애 개선 및 수면유도 조성물에 관한 것이다. The present invention relates to a composition for improving sleep disturbance and a composition for inducing sleeping, and more particularly, to a composition for preventing sleep disorder, which is composed of constituents derived from a natural product and which does not cause side effects of a synthetic medicine including phenobarbital and benzodiazepine, And has an affinity for the GABAA-benzodiazepine receptor, thereby improving the sleeping disorder, and a composition for inducing sleeping.
수면장애는 현대인들이 흔히 겪는 문제 중의 하나이다. 수면장애란 건강한 수면을 취하지 못하거나, 충분한 수면을 취하고 있음에도 낮 동안에 각성을 유지하지 못하는 상태, 또는 수면리듬이 흐트러져 있어서 잠자거나 깨어 있을 때 어려움을 겪는 상태를 말한다. 정신적인 문제가 큰 원인이 되기도 하는데 과도한 스트레스와 불안감, 긴장감, 공포 등으로 인해 발생한다. 수면장애는 인구의 약 20% 이상이 경험한 적이 있거나 앓고 있는 매우 흔한 질환이다. 수면장애는 여러 가지 개인적, 사회적 문제를 초래할 수 있으며 학습장애, 능률저하, 교통사고, 안전사고, 정서장애, 사회 적응장애, 결혼생활의 불만족, 그리고 산업재해 등의 원인이 된다. 또한 수면장애를 적절하게 치료하지 않으면 이미 앓고 있는 내과적, 신경과적, 정신과적 질환이 악화되거나 회복이 지연될 수 있고 심근경색증, 뇌졸중 등의 심각한 병을 초래할 수 있다. 따라서 현대인들은 수면보조제에 대한 관심이 높아지고 있다.Sleep disturbance is one of the most common problems of modern people. A sleeping disorder is a condition in which a person can not take a healthy sleep, is awake during the day despite having sufficient sleep, or has difficulty sleeping or awake when his sleep rhythm is disturbed. Mental problems are also a major cause, but they are caused by excessive stress, anxiety, tension, and fear. Sleep disorders are a very common disorder in which more than 20% of the population have experienced or are suffering. Sleep disturbances can cause a variety of personal and social problems and can be causes of learning disability, inefficiency, traffic accidents, safety accidents, emotional disturbances, social adjustment disorders, dissatisfaction with marriage, and industrial accidents. In addition, if the sleep disorder is not properly treated, the medical, neurological, and psychiatric illnesses that are already suffering may deteriorate or the recovery may be delayed, and serious diseases such as myocardial infarction and stroke may result. Therefore, modern people are increasingly interested in sleep aids.
치료 약물로는 벤조다이아제핀 계열의 약물과 세로토닌 효능약 등이 사용되고 있다. 벤조다이아제핀을 포함하여 많은 약물들이 GABAA 수용체에 결합하여 약리작용을 행하고 있고, 벤조다이아제핀 부위에 약물 또는 보조제가 결합하면 GABA에 대한 GABAA 수용체 친화도를 증진시키고, 염소 이온의 세포 내 유입을 증가시켜 불안 완화, 경련 개선, 진정 작용, 및 수면 유도 및 개선 효과를 보인다. GABAA 수용체는 멤브레인 이온 채널을 형성하는 펜타머릭 단백질로서, 진정, 수면, 불안, 근육긴장, 경련, 기억 상실 등의 조절과 밀접한 관련이 있고, 이를 통하여 GABA(감마-아미노부티르산)이 작용하게 된다. 이러한 약물들은 장기간 사용하였을 때 내성 및 의존성이 형성되는 부작용을 동반하며 근육완화 및 건망증 등의 심각한 문제를 초래하기도 한다. Benzodiazepines and serotonergic drugs have been used as therapeutic drugs. Many drugs, including benzodiazepines, bind to the GABAA receptor and perform pharmacological actions. When a drug or adjuvant is bound to the benzodiazepine site, the GABAA receptor affinity for GABA is enhanced and the intracellular influx of the chloride ion is increased Anxiety relief, seizure improvement, sedation, and sleep induction and improvement. The GABAA receptor is a pentameric protein that forms a membrane ion channel and is closely related to the regulation of sedation, sleep, anxiety, muscle tension, convulsions, memory loss, etc. through which GABA (gamma-aminobutyric acid) acts. These drugs, when used for a long period of time, are accompanied by side effects that result in resistance and dependence, and may cause serious problems such as muscle relaxation and forgetfulness.
따라서, 수면제 장기 복용자 및 제한자의 경우 이를 대체할 수 있는 수단으로 천연 보조제의 필요성이 높아지고 있으며, 수면 증진 건강기능식품에 대한 수요가 증대되고 있는 실정이다.Therefore, the need for natural supplements is increasing as a means of replacing sleeping pills in the case of long-term sleepers and restrictors, and the demand for functional foods for sleep enhancement is increasing.
대한민국 등록특허 등록번호 제10-0947353호는 수면장애 개선과 쾌면을 위한 건강식품 조성물에 관한 것으로서, 특히 천연물 중에서 쾌면에 도움을 준다고 알려진 산조인, 토란대, 연자육, 연근과 마그네슘으로 구성된 환으로 멜라토닌 함량이 높아 우수한 수면장애 개선 효능을 나타내는 수면 장애 개선과 쾌면을 위한 건강식품 조성물에 관하여 개시하고 있다.Korean Patent Registration No. 10-0947353 relates to a health food composition for improvement of sleeping disorder and a pleasant surface. Especially, it is a ring composed of a sanjoin, a tranquilizer, a livestock meat, a lotus root, and magnesium which are known to help the pleasant surface among natural products, and a melatonin content And a health food composition for improvement of sleeping disorder and a pleasant surface showing an excellent sleeping disorder improving effect.
대한민국 공개특허공보 공개번호 제10-2014-0030454호는 굴과 해조류의 혼합물을 발효시켜 천연 가바를 함유하는 스트레스 해소 또는 수면장애 개선용 발효소재 및 이의 제조방법에 관한 것으로서, 굴과 해조류의 혼합물을 발효시켜 다량의 천연 GABA를 함유하는 스트레스 해소 또는 수면장애 개선용 발효소재 및 이의 제조방법에 관한 것이다. 본 발명에 따른 굴과 다시마의 혼합물을 발효시켜 제조된 발효소재는 기존의 발효소재와 비교하여 다량의 타우린 및 GABA를 함유하며, 스트레스 억제 효과 및 수면장애 개선효과가 우수하다고 개시하고 있다.Korean Patent Laid-Open Publication No. 10-2014-0030454 relates to a fermentation material for relieving stress or improving sleeping disturbance containing a natural ga bar by fermenting a mixture of oysters and seaweeds, and a method for producing the fermented material, wherein a mixture of oysters and seaweeds And fermenting the fermented material to improve stress-relieving or sleeping disorder containing a large amount of natural GABA, and a process for producing the same. The fermented material prepared by fermenting a mixture of oysters and sea tangle according to the present invention contains a large amount of taurine and GABA as compared with conventional fermented materials, and has been shown to be excellent in stress suppressing effect and sleeping disorder improving effect.
본 발명은 천연물 유래의 구성성분들로 이루어져 페노바비탈류, 벤조다이아제핀류를 포함한 합성의약품이 가지는 부작용을 유발하지 않고, 안전성을 확보할 수 있으며, GABAA-벤조다이아제핀 수용체에 친화력을 가져 수면장애를 개선할 수 있는 수면장애 개선 및 수면유도 조성물을 제공하는데 그 목적이 있다.The present invention is based on the finding that the present invention can provide safety without causing side effects of synthetic drugs including phenobarbital, benzodiazepine, and the like, and has an affinity for GABAA-benzodiazepine receptor, And to provide a composition for improving sleep disorder and a composition for inducing sleeping which can be improved.
본 발명에 따른 수면장애 개선 및 수면유도 조성물은 카제인 또는 카제인 가수분해물 10 내지 90중량부와 염화칼륨 2 내지 10중량부를 포함한다.The sleep disorder improvement and sleep inducing composition according to the present invention comprises 10 to 90 parts by weight of casein or casein hydrolyzate and 2 to 10 parts by weight of potassium chloride.
상기 수면장애 개선 및 수면유도 조성물은 쥐오줌풀 추출물 1 내지 10중량부를 더 포함할 수 있다.The sleep-disorder improvement and sleep-inducing composition may further comprise 1 to 10 parts by weight of the Rhizome grass extract.
상기 쥐오줌풀 추출물은 쥐오줌풀 전초를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것일 수 있다.The above-mentioned Porphyra grass extract is obtained by immersing a dried pterygium outpost in a 10 to 70% ethanol aqueous solution of 15 to 25 times the total amount of the building, extracting it at a temperature within a range of 60 to 90 ° C for 2 to 8 hours, And the resulting extract may be concentrated and dried to be powdered.
상기 수면장애 개선 및 수면유도 조성물은 호프 추출물 1 내지 10중량부 또는 상추 추출물 1 내지 30중량부를 더 포함할 수 있다.The sleep disorder improvement and sleep inducing composition may further comprise 1 to 10 parts by weight of the hop extract or 1 to 30 parts by weight of the lettuce extract.
상기 호프 추출물은 호프를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것일 수 있다.The hop extract is prepared by dipping the dried hopper in a 10 to 70% ethanol aqueous solution of 15 to 25 times the total amount of the building, extracting the mixture at a temperature within the range of 60 to 90 ° C for 2 to 8 hours, It may be concentrated and dried to be powdered.
상기 상추 추출물은 상추 전초를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것일 수 있다.The extract of lettuce is prepared by immersing the dried lettuce plant in a 10 to 70% aqueous solution of ethanol in an amount of 15 to 25 times the total amount of the building, extracting it at a temperature within the range of 60 to 90 ° C for 2 to 8 hours, May be concentrated and dried to be powdered.
본 발명에 따르면, 천연물 유래의 구성성분들로 이루어져 페노바비탈류, 벤조다이아제핀류를 포함한 합성의약품이 가지는 부작용을 유발하지 않고, 안전성을 확보할 수 있으며, GABAA-벤조다이아제핀 수용체에 친화력을 가져 수면장애를 개선할 수 있는 수면장애 개선 및 수면유도 조성물을 제공하며, 그에 의하여 GABAA-벤조다이아제핀 수용체에 높은 친화력을 가져 수면 장애를 개선시킬 수 있으며, 복용 후, 수면 유지시간을 지속시키고 입면시간을 단축시키는 효과를 나타낼 수 있다. 또한 수면의 질을 개선시킴으로서 일상생활의 만족감을 높일 수 있다.According to the present invention, it is possible to secure safety without causing side effects of synthetic drugs including phenobarbital and benzodiazepine, which are composed of components derived from natural products, and have affinity to GABAA-benzodiazepine receptor, The present invention provides a composition for improving sleep disturbance and a composition for inducing a sleeping which can improve a sleep disorder, thereby providing a high affinity to the GABAA-benzodiazepine receptor, thereby improving sleep disorder, maintaining sleep maintenance time after taking, Can be reduced. In addition, by improving the quality of sleep, the satisfaction of daily life can be improved.
이하, 본 발명을 구체적인 실시예를 참조하여 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to specific examples.
본 발명에 따른 수면장애 개선 및 수면유도 조성물은 카제인 또는 카제인 가수분해물 10 내지 90중량부와 염화칼륨 2 내지 10중량부를 포함함을 특징으로 한다.The sleep disorder improvement and sleep inducing composition according to the present invention is characterized by comprising 10 to 90 parts by weight of casein or casein hydrolyzate and 2 to 10 parts by weight of potassium chloride.
본 발명에서는 식품원료로서 우유 유래의 카제인 또는 카제인 가수분해물과 염화칼륨 혼합물을 사용하여 수면 장애를 개선할 수 있으며, 가슴 떨림, 흥분성 고혈압과 수전증, 흥분으로 인한 일시적인 기억상실 및 수면장애 개선 및 수면유도 조성물로서 활용 가능함을 확인하고 본 발명을 완성하기에 이르렀다. 즉, 스트레스로 인한 혈압상승과 스트레스 호르몬의 분비 감소, 정서적 안정에 효과가 있는 우유 유래의 카제인과 염화칼륨의 혼합물을 기본으로 하고, 여기에 쥐오줌풀추출물 및/또는 호프추출물, 상추추출물 그리고 을 혼합 제조하여 부작용이 없고 수면장애 개선 및 수면유도 효과를 증대시키는 천연제품을 제조함으로써 본 발명을 완성시켰다. In the present invention, it is possible to improve the sleeping disorder by using casein or casein hydrolyzate derived from milk as a raw material of food or a mixture of potassium chloride and milk, and it is also possible to provide a composition for preventing sleep disturbance, And the present invention has been accomplished. That is, based on a mixture of milk-derived casein and potassium chloride, which is effective for increasing blood pressure due to stress, decreasing the secretion of stress hormone, and emotional stability, the mixture is prepared by mixing the extracts of Porphyra vulgaris and / Thereby producing a natural product which has no side effects and improves the sleeping disorder and induces a sleep inducing effect.
카제인(casein)은 우유의 주요단백질로서 일종의 인 단백질이며, αs-, β-, κ-카제인 및 기타 미량의 카제인들로 구성되어 있다. 우유 유래의 카제인은 스트레스로 인한 혈압 상승과 스트레스 호르몬의 분비 감소, 정서적인 안정 유지에 도움이 되는 것으로 알려져 있다. 우유 단백질인 카제인 속에 많이 함유 되어 있는 트립토판은 기분을 조절하는 '세로토닌'의 원료로 사용된다. 세로토닌이 신체 내의 수면을 조절하는 멜라토닌으로 전환되어 신경을 안정시키고 수면을 유도한다. 따라서 모유를 먹는 어린아이가 평온히 잠을 자는 것을 알 수 있다. 미국의 한 연구에 따르면, 신생아에게 트립토판을 함유한 조제분유를 먹였을 때 대조군 신생아에 비해 잠들기까지 걸리는 시간이 짧아진 것을 알 수 있다. 식품용으로서의 카제인은 모조유, 커피 크리머, 각종 가공곡류 식품, 소시지, 아이스크림믹스, 카제인플라스틱 토핑 등의 제조에 사용되고 있고, 카제인으로 만든 공업용 접착제는 목공용으로, 카제인플라스틱으로 만든 단추 등은 염색과 광택의 편리성 때문에 이들 용도로 사용되고 있다. 식품첨가물로는 카제인(rennet casein) 및 카제인나트륨(sodium caseinate, soda casein)이 있다. 카제인에는 유화작용, 증점작용, 보습작용이 있어, 이러한 기능을 이용하여 식품가공에 사용한다. 주된 용도는 모조 치즈, 커피 크리머나 분말크림, 육아용 분유, 빵류, 수산가공식품, 육류가공식품, 스파게티, 마요네즈 등이다.Casein is a major protein of milk and is a protein of phosphorus and consists of αs-, β-, κ-casein and other trace amounts of casein. Milk-derived casein is known to help increase blood pressure, reduce stress hormone secretion, and maintain emotional stability. Tryptophan, which is contained in milk protein casein, is used as a source of 'serotonin' to control mood. Serotonin is converted into melatonin that regulates sleep in the body, stabilizing the nerves and inducing sleep. Thus, a child who is breastfeeding can sleep comfortably. According to one study in the United States, feeding newborns with formula containing tryptophan has a shorter time to sleep than the control newborn. Casein as a foodstuff is used in the production of mock oil, coffee creamer, processed cereal food, sausage, ice cream mix, casein plastic topping, etc. Industrial adhesives made of casein are used for woodworking, and casein plastic buttons are used for dyeing They are used for these purposes because of the convenience of gloss. Food additives include rennet casein and sodium caseinate (soda casein). Casein has emulsifying, thickening, and moisturizing functions, and is used in food processing using these functions. Its main uses are imitation cheese, coffee creamer and powder cream, powdered milk for children, bakery products, processed fish products, processed meat products, spaghetti and mayonnaise.
카제인 가수분해물은 우유 단백질인 카제인을 열처리 한 후, 췌장 트립신(pancreatic trypsin)으로 효소분해하여 만들어진다. 지표성분은 [Phe-Phe-Ala-Pro-Glu-Val-Phe-Gly-Lys] 12개의 아미노산으로 구성된 펩타이드로 5 내지 6% 함량으로 표준화된 것을 상용적으로 구입하여 사용할 수 있다. 카제인 가수분해물은 체내에서 안지오텐신 I 변환효소의 활성을 낮추어주어 혈압을 낮추는 것으로 작용기전이 제안되고 있다. 고혈압을 유발시킨 동물에 카제인 가수분해물을 섭취시켰을 때, 혈압이 유의적으로 감소되는 것이 관찰되었다. 실제로 혈압이 높아 걱정하는 성인(수축기 혈압 200이하, 확장기 혈압 109이하)을 대상으로 카제인 가수분해물의 보충효과를 비교한 인체적용연구에서, 카제인 가수분해물의 보충은 혈압을 낮추는데 도움을 줄 수 있는 것으로 확인되었다. 확보된 자료의 결과는 일관성 있으나, 기반연구와 인체적용연구의 수가 충분하지 않아 기능성 등급은 "기타기능 II"에 해당한다. The casein hydrolyzate is made by heat-treating casein, a milk protein, and enzymatically digesting it with pancreatic trypsin. Phe-Phe-Ala-Pro-Glu-Val-Phe-Gly-Lys] peptides composed of 12 amino acids and standardized as 5-6% content can be commercially purchased and used. The casein hydrolyzate is proposed to lower the blood pressure by lowering the activity of angiotensin I converting enzyme in the body. When the casein hydrolyzate was ingested in hypertensive animals, blood pressure was significantly reduced. In a human application study comparing the supplementation effects of casein hydrolysates for adults who are worried about high blood pressure (systolic blood pressure lower than 200 and diastolic blood pressure lower than 109), supplementation of casein hydrolyzate may help lower blood pressure . The results of the ensured data are consistent, but the functional grade is equivalent to "Other Function II" due to insufficient number of studies in the base and human applications.
염화칼륨(potassium chloride)은 칼륨과 염소의 이온결합으로 이루어진 화합물이다. 염화칼륨에서 칼륨은 혈압을 낮춰 진정작용과 수면을 유도하는 것으로 알려져 있다. 칼륨은 우리 몸에서 이온(K+)의 상태로 세포내액에 다량으로 존재하며, 근육 및 신경의 기능조절에 관여하고 있는 전해질이다. 최근 연구에 따르면, 신경세포의 칼륨통로는 포유동물에 있어 깊은 수면 시 뇌에서 나타나는 서파를 발생시키는 데 중요한 역할을 하는 것으로 알려지고 있다. 염화칼륨에서 염소이온은 수면에서 중요한 작용을 하는 것으로 알려져 있다. 염소 이온이 이온통로를 통해 들어오게 되면 세포내부의 전위가 보다 더 마이너스를 띠게 되어 진정작용을 하게 된다. 보통의 식용 소금에는 나트륨의 함량이 88%로, 이 나트륨은 고혈압, 심장병, 뇌졸중 등을 유발할 수 있으며, 요즈음 우리나라처럼 소금을 많이 섭취하는 나라에서는 소금의 짠맛을 유지하면서 염화칼륨을 첨가하여 나트륨의 함량을 28 내지 60% 줄인 저나트륨 소금이 인기를 끌고 있다. 나트륨(Na)은 물을 끌어당기는 성질이 있어 혈압을 상승시키나, 칼륨(K)은 몸 속의 나트륨(Na)을 소변으로 배출시켜 혈압을 낮추는 효과를 보인다. 그러나 칼륨의 과잉섭취는 혈중 내 칼륨치를 높여 호흡곤란, 가슴통증, 심장마비 등을 일으킬 수 있어 매우 위험할 수 있다. 특히, 신장병 환자들이 복용하는 치료약에는 칼륨성분이 많이 포함된 약이 처방되는데, 이로 인하여 치명적인 위험에 노출될 수 있으므로 반드시 의사와 상의한 후 저나트륨 소금을 사용해야 한다. Potassium chloride is a compound consisting of potassium and chlorine ionic bonds. Potassium in potassium chloride is known to lower blood pressure and induce sedation and sleep. Potassium is an ion (K + ) in our body that exists in large amounts in the inner fluid of cells and is involved in the regulation of muscle and nerve function. Recent studies have shown that potassium channels in nerve cells play an important role in generating sleep in the brain during deep sleep in mammals. Chloride ion in potassium chloride is known to play an important role in sleeping. When chlorine ions enter through the ion channel, the potential inside the cell becomes more negative and becomes sedentary. The sodium content of common salt of edible salt is 88%, which can cause hypertension, heart disease, stroke, etc. In countries where salt is consumed as much as in our country these days, potassium chloride is added while maintaining salty taste of salt, Sodium salt, which is reduced by 28 to 60%, is gaining popularity. Sodium (Na) attracts water and increases blood pressure, but potassium (K) has the effect of lowering blood pressure by discharging sodium (Na) in urine to the body. However, excessive intake of potassium can lead to increased potassium levels in the blood, resulting in difficulty in breathing, chest pain, heart attack, etc., which can be very dangerous. In particular, medicines taken by patients with kidney disease are prescribed potassium-rich medicines, which can lead to fatal risks, so you should consult your doctor and use low sodium salt.
"카제인 또는 카제인 가수분해물 10 내지 90중량부와 염화칼륨 2 내지 10중량부"라는 구체적인 혼합비는 본 발명자들의 구체적인 실험을 통하여 수면장애 개선 및 수면유도에 최적의 혼합비로 선정한 것이다.The specific mixing ratio of "10 to 90 parts by weight of casein or casein hydrolyzate and 2 to 10 parts by weight of potassium chloride" was selected as the optimum mixing ratio for improvement of sleeping disorder and induction of sleep through concrete experiments of the present inventors.
상기 수면장애 개선 및 수면유도 조성물은 쥐오줌풀 추출물 1 내지 10중량부를 더 포함할 수 있다.The sleep-disorder improvement and sleep-inducing composition may further comprise 1 to 10 parts by weight of the Rhizome grass extract.
쥐오줌풀은 쌍떡잎식물 꼭두서니목 마타리과의 여러해살이 풀이다. 학명은 Valeriana fauriei이다. 산지의 다소 습한 곳에서 자란다. 땅속에서 가는 뿌리줄기가 옆으로 뻗으면서 번식하고, 뿌리는 수염뿌리이며 쥐 오줌 냄새와 비슷한 독특한 향기가 난다. 어린순을 나물로 먹는다. 쥐오줌풀의 뿌리 침출액은 건위, 두통, 진통에 효과가 있다. 한 연구에서 기분의 동요가 있는 환자에게 실험한 결과, 진정 효과가 있는 한편, 자극작용을 하여 피로회복에도 효과가 있는 것으로 밝혀졌다. 불안해소, 신경과민, 불면증에 탁월한 치료제다. 강심작용이 있어 두근거림을 진정시키기도 한다. 몇몇 연구에서 혈압을 낮추는 효과가 있는 것으로 밝혀졌다. 바레포트리암 성분은 항경련작용이 있으므로 신경성 소화 불량, 위경련, 과민성 위염에 탁월한 효과가 있다. 차를 피부 세정제(洗淨劑)로 사용하면 피부 염증을 진정시킨다. 정유는 화장품 재료나 담배의 향료로도 사용된다. 한방에서는 뿌리를 약재로 쓰는데, 정신불안증, 신경쇠약, 심근염, 산후심장병, 심박쇠약, 생리불순, 위경련, 관절염, 타박상에 효과가 있다. 열매에 털이 있는 것을 광릉쥐오줌풀(var. dasycarpa), 잎의 갈라진 조각 가장자리에 톱니가 없는 것을 긴잎쥐오줌풀(var. integra)이라고 한다. 유럽에서는 서양쥐오줌풀(var. officinalis)의 뿌리를 기원전부터 이뇨제, 진통제, 통경제로 사용하였으며, 현재는 히스테리와 노이로제 등에 사용한다. 쥐오줌풀을 대량으로 투여하면 중추신경을 마비시키고 대뇌피질의 억제과정을 강화해서 반사와 흥분성을 약화시키며 평활근의 경련을 풀어주는 약리작용; 부교감신경 흥분작용과 중추신경계 억제와 관련하여 혈압을 나주는 약리작용; 및 항균작용을 하고 면역결핍을 일으키는 바이러스를 차단하며 일부 항이뇨작용을 하는 약리작용;을 갖는 것으로 알려져 있다.It is a perennial plant of the perennial plant of the dicotyledonous plant. The scientific name is Valeriana fauriei . It grows in a somewhat humid place of mountain. The roots growing in the ground stretch as they grow to the side, and their roots are the roots of beard and have a unique smell similar to the smell of rat piss. She eats young seeds as herbs. Root leavening in the juvenile grass has effects on the condition, headache and pain. One study found that patients with mood swings had a sedative effect and were also effective in relieving fatigue by stimulating. It is an excellent treatment for relieving anxiety, nervousness and insomnia. It also has a radiant effect that calms the throbbing. Several studies have shown that it has the effect of lowering blood pressure. Barreport Liam has an anticonvulsant action, so it has an excellent effect on neurogenic dyspepsia, stomach cramps and irritable gastritis. Use tea as a skin cleanser to soothe skin inflammation. Essential oils are also used as cosmetics and fragrances for tobacco. In Oriental medicine, roots are used as medicines, which are effective in mental anxiety, nervous breakdown, myocarditis, postpartum heart disease, heart failure, menstrual irregularity, stomach cramps, arthritis and bruises. Gwangneung that hairy fruit valerian (var. Dasycarpa), and on the edge of the cracked pieces of leaves as ginip valerian (var. Integra) that does not have teeth. In Europe, the roots of var. Officinalis have been used as diuretics, analgesics, and tongue economics since BC, and are now used in hysteria and neurosis. The administration of large doses of the barley grass paralyzes the central nervous system and strengthens the cerebral cortex inhibition process, weakening reflexes and excitability, and releasing the smooth muscle spasm. Pharmacological actions that exert blood pressure in association with parasympathetic stimulation and inhibition of the central nervous system; And pharmacological actions that block antiviral and viruses that cause immune deficiency and have some antidiuretic action.
상기 쥐오줌풀 추출물은 쥐오줌풀 전초를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것일 수 있다.The above-mentioned Porphyra grass extract is obtained by immersing a dried pterygium outpost in a 10 to 70% ethanol aqueous solution of 15 to 25 times the total amount of the building, extracting it at a temperature within a range of 60 to 90 ° C for 2 to 8 hours, And the resulting extract may be concentrated and dried to be powdered.
상기 수면장애 개선 및 수면유도 조성물은 호프 추출물 1 내지 10중량부 또는 상추 추출물 1 내지 30중량부를 더 포함할 수 있다.The sleep disorder improvement and sleep inducing composition may further comprise 1 to 10 parts by weight of the hop extract or 1 to 30 parts by weight of the lettuce extract.
호프(hop)는 뽕나무과에 속하는 유럽원산의 다년성 만성초본 Humulus lupulus로 암꽃을 음건한 것이다. 자웅이주로 맥주에는 암그루의 수정하지 않은 암꽃을 쓴다. 호프는 신경 진정 효과와 수면유도 효과가 있어 불안증과 불면증 치료에 도움이 된다. 멜라토닌과 유사한 작용을 하여 몸의 체온을 내려 잠을 촉진시키는 역할을 한다.Hope is a multi-year-old chronic herbaceous Humulus lupulus of European origin belonging to the genus Phalaenopsis . The male predominantly uses unmodified female flowers of beech. Hope has a nerve sedative effect and sleep inducing effect, which helps to treat anxiety and insomnia. It acts like melatonin to lower body temperature and promote sleep.
상기 호프 추출물은 호프를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것일 수 있다.The hop extract is prepared by dipping the dried hopper in a 10 to 70% ethanol aqueous solution of 15 to 25 times the total amount of the building, extracting the mixture at a temperature within the range of 60 to 90 ° C for 2 to 8 hours, It may be concentrated and dried to be powdered.
상추(lettuce)는 요약쌍떡잎식물 초롱꽃목 국화과의 한해살이 풀이다. 학명은 Lactuca sativa이다. 유럽과 서아시아가 원산지이고 채소로 널리 재배한다. 줄기는 가지가 많이 갈라지고 높이가 90 내지 120cm이며 전체에 털이 없다. 많은 품종이 있으며, 꽃줄기가 나오기 전에 잎을 따서 식용한다. 상추의 쓴맛 성분인 BSL(Bitter sesquiterpene lactones)이 진정작용과 숙면효과가 있다는 과학적 연구결과가 발표되었다. 한방에서는 뿌리를 제외한 식물체 전체와 종자를 약재로 쓰는데, 식물체는 소변 출혈과 산모의 젖이 부족할 때 효과가 있고, 종자는 고혈압과 산모의 젖이 부족할 때 물을 넣고 달여서 복용한다. 상추는 재배 역사가 매우 오래 되어 기원전 4500년경의 고대 이집트 피라미드 벽화에 작물로 기록됐으며, 기원전 550년에 페르시아 왕의 식탁에 올랐다는 기록도 있고, 그리스, 로마 시대에 중요한 채소로 재배하였다고 한다. 중국에는 당나라 때인 713년의 문헌에 처음 등장하고, 한국에는 연대가 확실하지 않으나 중국을 거쳐 전래되었으며, 중국의 문헌에는 고려의 상추가 질이 좋다는 기록이 있다. 현재는 한국, 중국, 일본, 미국, 영국 등 넓은 지역에서 재배되는데, 재배되는 상추는 품종이 많이 분화되어 크게 결구상추(var. capitata), 잎상추(var. crispa), 배추상추(var. longifolia), 줄기상추(var. asparagina)의 4가지 변종으로 나뉜다. 상추는 주로 샐러드나 쌈을 싸 먹는데 이용되고, 겉절이로도 먹는다. 비타민과 무기질이 풍부하여 빈혈 환자에게 좋으며, 줄기에서 나오는 우윳빛 즙액에 락투세린과 락투신이 들어 있는데, 이것이 진통과 최면 효과가 있어 상추를 많이 먹으면 잠이 온다. Lettuce is an annual plant of dicotyledonous plants. The scientific name is Lactuca It is sativa . It is native to Europe and West Asia and is widely grown as a vegetable. The trunk is divided into many branches, the height is 90 to 120 cm, and there are no hairs in the whole. There are many varieties, and the leaves are edible before the stem of the flower emerges. Bitter sesquiterpene lactones (BSL), a bitter component of lettuce, has been shown to have sedative and sleep effects. In one room, whole plants and seeds are used as medicines except for roots. Plants are effective when there is insufficient blood in urine and mother's milk. Seeds are watered and dalyeose when hypertension and mother's milk are insufficient. Lettuce has a very long history of cultivation and was recorded as a crop on ancient Egyptian pyramid murals dating back to about 4500 BCE. It was also recorded as a table of Persian kings in 550 BC, and grew as a significant vegetable in Greek and Roman times. In China, it first appeared in the Tang Dynasty, the 713th year of the year. In Korea, the date is not certain, but it was introduced through China. Currently, there is grown in large areas, such as South Korea, China, Japan, USA, UK, grown lettuce greatly envoys are varieties differentiation lot of lettuce (var. Capitata), ipsangchu (var. Crispa), cabbage lettuce (var. Longifolia) , And stem lettuce ( var. Asparagina ). Lettuce is mainly used for wrapping salads and wrappers, and it also eats roots. It is rich in vitamins and minerals, and is good for anemic patients. Lactucerin and lactic acid are contained in the juvenile juice from the stalk. It has analgesic and hypnotic effects.
상기 상추 추출물은 상추 전초를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것일 수 있다.The extract of lettuce is prepared by immersing the dried lettuce plant in a 10 to 70% aqueous solution of ethanol in an amount of 15 to 25 times the total amount of the building, extracting it at a temperature within the range of 60 to 90 ° C for 2 to 8 hours, May be concentrated and dried to be powdered.
상기한 바의 본 발명에 따른 조성물은 상기한 성분을 주성분으로 하고, 약학적, 식품학적으로 허용 가능한 담체, 예를 들면 비타민 등으로부터 이루어진 선택된 조합을 부가성분으로 포함할 수 있다.The composition according to the present invention as described above may contain, as a main component, the above-mentioned components and a combination of a pharmaceutically and pharmaceutically acceptable carrier such as vitamins as an additional ingredient.
상기한 바의 본 발명에 따른 조성물은 상기 성분에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. The above-described composition according to the present invention may further contain one or more active ingredients showing the same or similar functions in addition to the above components.
이하에서 본 발명의 바람직한 실시예 및 비교예들이 기술되어질 것이다.Hereinafter, preferred embodiments and comparative examples of the present invention will be described.
이하의 실시예들은 본 발명을 예증하기 위한 것으로서 본 발명의 범위를 국한시키는 것으로 이해되어져서는 안될 것이다.The following examples are intended to illustrate the invention and should not be construed as limiting the scope of the invention.
제조예Manufacturing example 1 내지 6 1 to 6
하기 표 1에 나타낸 바와 같이 건조된 쥐오줌풀, 호프 및 상추를 사용하여 이들 식물 건물들 각각을 건물의 총량 대비 20배수의 양의 20% 에탄올(주정 알코올) 및 60% 에탄올(주정 알코올)에 침지시키고, 80℃에서 5시간 동안 추출하였다. 그 후 와트만 여과지로 여과한 후, 추출액을 60℃에서 감암 농축 및 건조시켜 분말로 수득하였다.Each of these plant buildings was harvested from the building using the dried persimmon grass, hops and lettuce as shown in Table 1 below. Was immersed in 20% ethanol (alcohol alcohol) and 60% ethanol (alcohol alcohol) in an amount of 20 times the total amount and extracted at 80 DEG C for 5 hours. After filtration through Watman filter paper, the extract was concentrated under reduced pressure at 60 ° C and dried to give a powder.
실시예Example 1 내지 4 및 1 to 4 and 비교예Comparative Example 1 내지 3 1 to 3
카제인, 염화칼륨, 상기 제조예 1 내지 6에서 수득된 추출물을 사용하여 하기 표 2에 나타낸 비율로 혼합(중량부 기준)하여 수면장애 개선 및 수면유도 조성물을 제조하였으며, 후속하는 실험들에서 사용하였다.Casein, potassium chloride and the extracts obtained in the above Preparation Examples 1 to 6 were used to prepare a composition for improving sleep disturbance and a sleeping composition by mixing (parts by weight) in the proportions shown in the following Table 2 and used in the following experiments.
(제조예 1)Swallow grass extract
(Production Example 1)
(제조예 2)Hop extract
(Production Example 2)
(제조예 3)Lettuce extract
(Production Example 3)
실험예Experimental Example 1: One: GABAAGABAA -- 벤조다이아제핀Benzodiazepine 수용체 결합 활성 탐색 Detection of receptor binding activity
GABAA-벤조다이아제핀 수용체 결합 활성 측정은 마우스의 대뇌피질을 적출한 후, 즉시 30 mM 트리스-염산(Tris-HCl) 완충제(pH 7.4, 4℃) 20 ㎖에 넣어 균질화시키고 10초 동안 초음파를 처리하였다. 이후 27,000×g 및 4℃의 조건에서 15분간 원심분리한 후, 상층액을 버리고 다시 완충제 20 ㎖로 원심분리하는 과정을 3번 반복하였다. 뇌 조직 안의 GABA를 제거하기 위하여 37℃의 수조에서 30분간 정치하여 원심분리한 후, 펠릿을 수집하여 -80℃에서 동결보관하여 사용하였다. 동결된 막을 해동시킨 후, 27,000×g 및 4℃에서 10분간 원심분리한 후, 상층액을 버리고 90 mM 트리스-시트르산염(Tris-citrate) 완충제(결합 완충제, pH 7.1, 4℃) 20 ㎖로 원심분리과정을 3번 반복한 후, 막을 결합 완충제에 900 ㎖ 완충제/원래 조직(g)의 농도로 현탁시켜 결합력 평가 시험에 사용하였다. 96-웰 플레이트에 막 현탁액 180 ㎕, 제조예 1 내지 6의 추출물 시료, 실시예 1 내지 7 그리고 비교예 1 내지 2 및 대조예 1 각각 10 ㎕ 및 3H-플루마제닐 (1 nM, 최종 농도) 10 ㎕을 넣고 빙욕(ice-bath)에서 40분간 반응시켰다. 이후, 유리섬유 필터(GF/C, Whatman)을 이용하여 수집하였다. 샘플의 방사선 활성(radioactivity)은 Tri-Carb Liquid Scintillation Analyzers (Perkin-Elmer, Shelton, CT, USA)로 측정되었다. 비특이적 결합(nonspecific binding, NSB)은 클로나제팜(1 μM, 최종 농도)을 이용하여 그 값을 결정하였고, 결합 변위(binding displacement) 값(%)은 아래와 같이 계산하였다.The GABAA-benzodiazepine receptor binding activity was measured by homogenizing the mouse cerebral cortex and immediately adding it to 20 ml of 30 mM Tris-HCl buffer (pH 7.4, 4 ° C) and sonication for 10 seconds Respectively. After centrifugation at 27,000 × g and 4 ° C. for 15 minutes, the supernatant was discarded and centrifuged again with 20 ml of buffer. This procedure was repeated three times. To remove GABA in the brain tissue, the cells were allowed to stand in a 37 ° C water bath for 30 minutes and centrifuged. The pellets were collected and stored at -80 ° C for freezing. The frozen membranes were thawed and centrifuged at 27,000 × g and 4 ° C. for 10 min. The supernatant was discarded and 20 ml of 90 mM Tris-citrate buffer (binding buffer, pH 7.1, 4 ° C.) After the centrifugation procedure was repeated three times, the membrane was suspended in binding buffer at a concentration of 900 ml buffer / original tissue (g) and used for the binding force assay. To a 96-well plate were added 180 μl of the membrane suspension, 10 μl each of the extract samples of Preparation Examples 1 to 6, Examples 1 to 7 and Comparative Examples 1 and 2 and Control Example 1, and 3 μl-flumazenil (1 nM, final concentration ) Were added and reacted in an ice-bath for 40 minutes. Then, they were collected using a glass fiber filter (GF / C, Whatman). The radioactivity of the samples was measured with Tri-Carb Liquid Scintillation Analyzers (Perkin-Elmer, Shelton, CT, USA). The nonspecific binding (NSB) was determined using clonazepam (1 μM, final concentration) and the binding displacement value (%) was calculated as follows.
결합 변위(%) = [1 ((시료의 DPM NSBDPM)/(TB DPM NSB DPM))]×100 Bond displacement (%) = [1 ((DPM NSBDPM of the sample) / (TB DPM NSB DPM)]] 100
여기에서, DPM은 분 당 분해이고, TB는 총 결합이고, NSB는 비특이적 결합이다.Here, DPM is decomposition per minute, TB is total bond, and NSB is non-specific binding.
벤조다이아제핀 수용체의 선택적인 길항제인 3H-플루마제닐의 수용체에 대한 결합 반응을 억제하는 활성도를 측정한 결과, 상기 표 3에 나타난 바와 같이, 제조예 1의 쥐오줌풀 추출물(20% 알코올 추출)이 제조예 4의 쥐오줌풀 추출물(60% 알코올 추출) 보다 우수하고, 제조예 2의 호프 추출물(20% 알코올 추출)이 제조예 5의 호프 추출물(60% 알코올 추출) 보다 우수하고, 제조예 3의 상추 추출물(20% 알코올 추출)이 제조예 6의 상추 추출물(60% 알코올 추출) 보다 우수함을 확인할 수 있었으며, 후속의 실시예들에서는 제조예 1의 쥐오줌풀 추출물(20% 알코올 추출), 제조예 2의 호프 추출물(20% 알코올 추출) 및 제조예 3의 상추 추출물(20% 알코올 추출)을 사용하였다.The activity of inhibiting the binding reaction of 3 H-flumazenil to the receptor, which is a selective antagonist of the benzodiazepine receptor, was measured. As shown in the above Table 3, the crude extract of Preparation 1 (20% alcohol extract ) Was superior to the crude extract (60% alcohol extract) of Production Example 4, and the hop extract of Production Example 2 (20% alcohol extraction) was superior to the hop extract of Production Example 5 (60% 3 extract of lettuce (20% alcohol extract) was superior to the extract of lettuce (60% alcohol extract) of Preparation Example 6. In the following Examples, (20% alcohol extract) of Preparation Example 2 and a lettuce extract (20% alcohol extract) of Preparation Example 3 were used.
또한, 비교예 1의 카제인 단독과 비교예 2의 염화칼륨 단독에 비하여 실시예 1의 카제인과 염화칼륨의 혼합물이 더 우수함을 확인할 수 있었으며, 실시예 1에 호프 추출물, 상추 추출물 또는 호프 추출물과 상추 추출물의 혼합물을 더 추가한 실시예들이 더 우수함을 확인할 수 있었으며, 이들 중에서도 쥐오줌풀 추출물이 4중량부로 포함된 실시예(실시예 4)가 가장 우수함을 확인할 수 있었다.In addition, it was confirmed that the mixture of casein and potassium chloride of Example 1 was superior to casein alone of Comparative Example 1 and potassium chloride alone of Comparative Example 2. In Example 1, it was confirmed that the mixture of hop extract, lettuce extract or hop extract and lettuce extract (Example 4) containing 4 parts by weight of Rhizome vulgaris extract was found to be the most excellent.
실험예Experimental Example 2: 2: 실시예Example 4 및 4 and 비교예Comparative Example 1 내지 3의 수면유도효과 동물 실험 Sleep-inducing effects of 1 to 3 Animal experiments
수면유도 시험 동물로는 체중 15 내지 20g ICR 수컷 마우스를 사용하였다. 사육조건은 22±2℃, 상대습도 55±5%, 환기횟수 시간당 10 내지 12회, 명암주기 12시간으로 유지하고, 모든 실험동물은 실험 동물실에서 1주일간 적응시킨 후, 실험에 사용하였다. 시료는 1일 1회로 5일간 투여하였고, 최종 시료의 경구투여 30분 후에 pentobarbital(30 ㎎/㎏)을 마우스 복강으로 주사하여 수면시간(sleeping time)(표 4)과 입면시간(sleep latency)(표 5)을 측정하였다. 대조군은 무투여로 하였다.An ICR male mouse weighing 15 to 20 g was used as the sleep inducing test animal. Breeding conditions were maintained at 22 ± 2 ℃, 55 ± 5% relative humidity, 10-12 times per hour of ventilation, 12 hours of light cycle, and all experimental animals were adapted for one week in the laboratory animal room. Samples were administered once a day for 5 days. After 30 minutes of oral administration of the final sample, pentobarbital (30 mg / kg) was injected into mouse abdominal cavity to induce sleeping time (Table 4) and sleep latency Table 5) were measured. The control group was not administered.
실험 결과, 비교예 1의 카제인 단독과 비교예 2의 염화칼륨 단독에 비하여 실시예 1의 카제인과 염화칼륨의 혼합물이 수면시간은 길어지고, 입면시간은 짧아짐을 확인할 수 있었으며, 쥐오줌풀 추출물이 4중량부로 포함된 실시예(실시예 4)가 수면시간이 가장 길었으며, 입면시간이 가장 짧은 것을 알 수 있었다.As a result of the experiment, it was confirmed that the mixture of casein and potassium chloride of Example 1 alone was longer than that of casein alone of Comparative Example 1 and potassium chloride alone of Comparative Example 2, It was found that the included embodiment (Example 4) had the longest sleeping time and the shortest rise time.
실험예Experimental Example 3: 3: 실시예Example 4의 수면유도효과 간이임상 실험 4 Sleep-Induced Efficacy Simplified Clinical Trials
수면장애를 겪고 있는 성인 남녀 30명에게 섭취 전 설문조사를 실시하고 실시예 섭취군과 위약 섭취군으로 15명씩 나누어 4주간 복용한 후, 다음과 같은 항목으로 설문조사를 실시하였다. 설문지 내용은 하기 표 6과, 점수표는 표 7과 같으며, 해당되는 곳에 표시를 하여 각 문항의 점수를 합산하여 결과를 표 8에 나타내었다.The questionnaire was administered to 30 adult men and women who were suffering from sleep disturbances. The subjects were divided into 15 groups according to the intake of the study group and the placebo group for 4 weeks. The contents of the questionnaire are shown in Table 6, and the score table is as shown in Table 7. The scores of each question are added together and the results are shown in Table 8.
섭취 후Example 4
After ingestion
섭취 후 개선율(%)Example 4
Improvement rate after ingestion (%)
섭취 전Placebo
Before ingestion
섭취 후Placebo
After ingestion
섭취 후 개선율(%)Placebo
Improvement rate after ingestion (%)
간이임상 결과, 실시예 4를 섭취한 군에서 평균적으로 90% 이상 수면장애가 개선되는 것을 확인할 수 있었으며, 위약 대조군과 비교하였을 때, 실시예 4가 수면장애 개선 및 수면 유도 효과가 확실히 나타나는 것을 알 수 있었다.As a result of the simple clinical results, it was confirmed that the sleeping disorder was improved by 90% or more on average in the group ingesting the Example 4, and that the Example 4 clearly improved the sleeping disorder and the sleep inducing effect when compared with the placebo control group there was.
이상에서 본 발명은 기재된 구체예에 대해서만 상세히 설명되었지만 본 발명의 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속함은 당연한 것이다.While the invention has been shown and described with reference to certain exemplary embodiments thereof, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (6)
수면장애 개선 및 수면유도 조성물은 쥐오줌풀 추출물 1 내지 10중량부를 더 포함함을 특징으로 하는 수면장애 개선 및 수면유도 조성물.The method according to claim 1,
A composition for improving sleep disturbance and a composition for sleep inducing sleep characterized in that the composition for improving sleep disturbance and the composition for sleep inducing further comprise 1 to 10 parts by weight of a crude extract.
상기 쥐오줌풀 추출물은 쥐오줌풀 전초를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것임을 특징으로 하는 수면장애 개선 및 수면유도 조성물.3. The method of claim 2,
The above-mentioned Porphyra grass extract is obtained by immersing a dried pterygium outpost in a 10 to 70% ethanol aqueous solution of 15 to 25 times the total amount of the building, extracting it at a temperature within a range of 60 to 90 ° C for 2 to 8 hours, Wherein the extract is concentrated and dried to be powdered.
상기 수면장애 개선 및 수면유도 조성물은 호프 추출물 1 내지 10중량부 또는 상추 추출물 1 내지 30중량부를 더 포함함을 특징으로 하는 수면장애 개선 및 수면유도 조성물.The method according to claim 1,
Wherein the sleep disorder improvement and sleep inducing composition further comprises 1 to 10 parts by weight of the hop extract or 1 to 30 parts by weight of the extract of lettuce.
상기 호프 추출물은 호프를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것임을 특징으로 하는 수면장애 개선 및 수면유도 조성물.5. The method of claim 4,
The hop extract is prepared by dipping the dried hopper in a 10 to 70% ethanol aqueous solution of 15 to 25 times the total amount of the building, extracting the mixture at a temperature within the range of 60 to 90 ° C for 2 to 8 hours, And the composition is pulverized, concentrated and dried to be powdered.
상기 상추 추출물은 상추 전초를 건조시킨 건물을 건물 총량 기준 15 내지 25배량의 10 내지 70% 에탄올 수용액에 침지시키고, 60 내지 90℃의 범위 이내의 온도에서 2 내지 8시간 동안 추출한 후, 수득된 추출액을 농축 및 건조시켜 분말화한 것임을 특징으로 하는 수면장애 개선 및 수면유도 조성물.5. The method of claim 4,
The extract of lettuce is prepared by immersing the dried lettuce plant in a 10 to 70% aqueous solution of ethanol in an amount of 15 to 25 times the total amount of the building, extracting it at a temperature within the range of 60 to 90 ° C for 2 to 8 hours, Is concentrated and dried and powdered. ≪ RTI ID = 0.0 > 11. < / RTI >
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160053430A KR101820761B1 (en) | 2016-04-29 | 2016-04-29 | Composition for improving sleep disturbance and sleep inducing |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160053430A KR101820761B1 (en) | 2016-04-29 | 2016-04-29 | Composition for improving sleep disturbance and sleep inducing |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170123534A KR20170123534A (en) | 2017-11-08 |
KR101820761B1 true KR101820761B1 (en) | 2018-01-22 |
Family
ID=60385444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160053430A KR101820761B1 (en) | 2016-04-29 | 2016-04-29 | Composition for improving sleep disturbance and sleep inducing |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101820761B1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200065713A (en) | 2018-11-30 | 2020-06-09 | 한국식품연구원 | A composition for the prevention or treatment of sleep disorders containing Ledebouriella seseloides extract |
KR20210047415A (en) | 2019-10-21 | 2021-04-30 | 한국식품연구원 | A composition for reducing side effects of GABAA receptor agonist, comprising phloroglucinol as an effective ingredient |
KR20210047414A (en) | 2019-10-21 | 2021-04-30 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa extract |
KR20210047416A (en) | 2019-10-21 | 2021-04-30 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa complex extracts |
KR20220042661A (en) | 2020-09-28 | 2022-04-05 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Glehnia littoralis extract |
KR20220056941A (en) | 2020-10-29 | 2022-05-09 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia with reduced side effects of GABAA receptor agonist, containing Glehnia littoralis extract |
KR102400107B1 (en) | 2022-01-20 | 2022-05-19 | 주식회사 비상썬라이즈 | A composition for sleep induction and diet and manufacturing method thereof |
KR20220157663A (en) | 2021-05-21 | 2022-11-29 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Angelica dahurica extract |
KR102564539B1 (en) | 2022-12-16 | 2023-08-09 | 부경대학교 산학협력단 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Codium fragile extract |
KR102646051B1 (en) | 2022-09-22 | 2024-03-13 | 국립부경대학교 산학협력단 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Gelidium amansii extract |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102245027B1 (en) * | 2017-11-20 | 2021-04-29 | 종근당건강 주식회사 | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient |
KR102109980B1 (en) * | 2018-03-20 | 2020-05-12 | 재단법인 경북바이오산업연구원 | Compositions for sound sleep comprising the extraction of lettuce, tuckahoe and rosemary and its manufacturing methods |
KR101980623B1 (en) | 2018-12-06 | 2019-08-28 | 김재현 | Aromatic composition for sleep induction and manufacturing method thereof |
KR102450531B1 (en) * | 2019-01-28 | 2022-10-05 | 닉스 주식회사 | System for inducing sleep using carbon dioxide |
KR102148613B1 (en) * | 2019-01-28 | 2020-10-14 | 닉스 주식회사 | System for inducing sleep using carbon dioxide |
KR102389771B1 (en) * | 2019-11-25 | 2022-04-22 | 조동기 | Method of manufacturing sleep induction difference and teeth using valerian |
KR102133447B1 (en) | 2020-01-28 | 2020-07-14 | 주식회사 다나을 | Drink for improving sleep disturbance and sleep inducing, and Manufacturing Method of the Same |
KR102513980B1 (en) * | 2020-10-19 | 2023-03-24 | 재단법인 전남바이오산업진흥원 | Medi-food composition for induce deep sleep |
KR20230115429A (en) | 2022-01-27 | 2023-08-03 | 동의대학교 산학협력단 | Composition for preventing or improving sleep disorder comprising lettuce extract, and method for producing candy using the same |
CN117482214A (en) * | 2023-10-23 | 2024-02-02 | 广州绿萃生物科技有限公司 | Hydrolyzed casein peptide for improving insomnia of middle-aged and elderly people and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009013143A (en) * | 2007-07-09 | 2009-01-22 | Nisshin Pharma Inc | Sleep-improving composition |
-
2016
- 2016-04-29 KR KR1020160053430A patent/KR101820761B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009013143A (en) * | 2007-07-09 | 2009-01-22 | Nisshin Pharma Inc | Sleep-improving composition |
Non-Patent Citations (1)
Title |
---|
Wien Med Wochenschr. 2007, Vol.157, pp.367-370* |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200065713A (en) | 2018-11-30 | 2020-06-09 | 한국식품연구원 | A composition for the prevention or treatment of sleep disorders containing Ledebouriella seseloides extract |
KR20210047415A (en) | 2019-10-21 | 2021-04-30 | 한국식품연구원 | A composition for reducing side effects of GABAA receptor agonist, comprising phloroglucinol as an effective ingredient |
KR20210047414A (en) | 2019-10-21 | 2021-04-30 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa extract |
KR20210047416A (en) | 2019-10-21 | 2021-04-30 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa complex extracts |
KR20220042661A (en) | 2020-09-28 | 2022-04-05 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Glehnia littoralis extract |
KR20220056941A (en) | 2020-10-29 | 2022-05-09 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia with reduced side effects of GABAA receptor agonist, containing Glehnia littoralis extract |
KR20220157663A (en) | 2021-05-21 | 2022-11-29 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Angelica dahurica extract |
KR102400107B1 (en) | 2022-01-20 | 2022-05-19 | 주식회사 비상썬라이즈 | A composition for sleep induction and diet and manufacturing method thereof |
KR102646051B1 (en) | 2022-09-22 | 2024-03-13 | 국립부경대학교 산학협력단 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Gelidium amansii extract |
KR102564539B1 (en) | 2022-12-16 | 2023-08-09 | 부경대학교 산학협력단 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Codium fragile extract |
Also Published As
Publication number | Publication date |
---|---|
KR20170123534A (en) | 2017-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101820761B1 (en) | Composition for improving sleep disturbance and sleep inducing | |
CN103976427A (en) | Passion fruit and blueberry juice drink and preparation method thereof | |
CN104738374A (en) | Passion fruit jam and production method thereof | |
CN102113535A (en) | Nutritious Moringa biscuit | |
CN105341947B (en) | Nutrient powder bags capable of improving sleep | |
CN104382050B (en) | A kind of antitoxic heart-soothing and sedative, help the health products of sleep | |
CN102160664A (en) | Nutritious drink for children | |
CN102524624A (en) | Bee product with function of improving sleeping and preparation method thereof | |
CN105029606A (en) | Preparation method of jasmine vinegar beverage | |
CN104304482A (en) | Passion fruit flavor dairy product | |
CN103238889B (en) | Anti-fatigue apple vinegar health beverage and preparation method thereof | |
KR101333152B1 (en) | Honey containing lavender | |
Koner et al. | Natural and artificial beverages: Exploring the pros and cons | |
CN102742894A (en) | Bee pollen-wolfberry oral liquid and preparation method thereof | |
CN105029553A (en) | Fruit juice-egg-calcium traditional Chinese medicine health beverage and preparation method thereof | |
CN104171485A (en) | Anti-aging honey | |
CN101708023A (en) | Honey tea | |
CN103689089A (en) | Pollen and almond powder beverage and preparation method thereof | |
KR101642176B1 (en) | Composition for enhancing growth and reinforcing immunity | |
CN116210831A (en) | Sleep-aiding dragon fruit fermented beverage and preparation method thereof | |
CN104223251A (en) | Passion fruit and pine needle tea drink | |
US20220061360A1 (en) | Health functional beverage | |
KR101041044B1 (en) | A composition for reducing sleep induction time and prolonging sleeping time, and a method for preparing the same | |
KR20200061285A (en) | Food Composition for blood circulation and for Preventing blood vessel disease Comprising Extract of Galangal | |
KR101720927B1 (en) | A process for the preparation of functional beverage comprising balloon flower root and bamboo extracts and the functional beverages prepared therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |